entertainment -WSS

entertainment

author：fashion 2025-09-27 16:46:58 - browse：69

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

explore

WSS

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Oprah kicked off a national conversation on obesity. Let's have it

Eye stem cell transplant could help restore vision in injured people

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

FDA approves first treatment for ultra

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

focus

entertainment

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Living with Hashimoto's and celiac disease, and med school, too

Wildfire smoke exposes gaps in outdoor worker protections

Covid vaccine financial winners and losers, from Pfizer to Novavax

Psychedelics group wrestles with new pharma identity

Vertex Pharmaceuticals may move headquarters in Boston

Walensky prepares to leave CDC — and Congress — behind

FDA approves first treatment for ultra

Affirmative action in medical school literally saved lives

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

entertainment

Ukraine taking heavy casualties 10 weeks into its counteroffensive

FDA approves first treatment for ultra

FDA's naming rule on biosimilars has undermined competition

Supreme Court mifepristone arguments center on docs' right to sue

The Readout: Lenmeldy, GLP

Why the world’s most expensive drug might be worth the price

explore

hotspot

hotspot

explore